Svasti Haricharan, Ph.D.
Lab Website
Svasti Haricharan's Research Focus
Dr. Haricharan's lab focuses on the role of DNA damage repair in inducing resistance to endocrine therapy in breast cancer, particularly the role of HER2/4 in mismatch repair deficiency, and in identifying early driver mutations in breast cancer formation.
Svasti Haricharan's Bio
Haricharan received her B.Sc. from Stella Maris College in Chennai, India, her M.Sc. from the University of Leicester, UK , and her Ph.D. in Molecular and Cellular Biology from Baylor College of Medicine. Haricharan completed 2 years of postdoctoral training at MD Anderson Cancer Center studying the effect of mutation load on breast cancer, before moving to Baylor College of Medicine for her second postdoctoral position focused on breast cancer genomics, where she was promoted to Research Assistant Professor. As junior mentored faculty at Baylor College of Medicine, she developed a research program studying non-canonical roles for DNA damage repair defects in cancer. In October 2018, Haricharan joined the faculty at Sanford Burnham Prebys as an Assistant Professor in the Tumor Microenvironment and Cancer Immunology Program.
Funding awards and collaborative grants
Department of Defense Breast Research Program Breakthrough Award
Susan G Komen Career Catalyst Research Award
Honors and recognition
2015-17: SU2C Laura Ziskin Postdoctoral Fellow
2013-15: NCI Cancer Prevention Research Training Fellowship
Publications
Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness.
Oropeza E, Seker S, Carrel S, Mazumder A, Lozano D, Jimenez A, VandenHeuvel SN, Noltensmeyer DA, Punturi NB, Lei JT, Lim B, Waltz SE, Raghavan SA, Bainbridge MN, Haricharan S
Sci Adv 2023 Jun 30 ;9(26):eadf2860
Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer.
Lovejoy LA, Shriver CD, Haricharan S, Ellsworth RE
Int J Environ Res Public Health 2023 Feb 7 ;20(4)
Research Silos in Cancer Disparities: Obstacles to Improving Clinical Outcomes for Underserved Patient Populations.
Richardson A, Darst B, Wojcik G, Wagle N, Haricharan S
Clin Cancer Res 2023 Apr 3 ;29(7):1194-1199
Decellularized organ biomatrices facilitate quantifiable in vitro 3D cancer metastasis models.
VandenHeuvel SN, Farris HA, Noltensmeyer DA, Roy S, Donehoo DA, Kopetz S, Haricharan S, Walsh AJ, Raghavan S
Soft Matter 2022 Aug 10 ;18(31):5791-5806
Endocannabinoid dysfunction in neurological disease: neuro-ocular DAGLA-related syndrome.
Bainbridge MN, Mazumder A, Ogasawara D, Abou Jamra R, Bernard G, Bertini E, Burglen L, Cope H, Crawford A, Derksen A, Dure L, Gantz E, Koch-Hogrebe M, Hurst ACE, Mahida S, Marshall P, Micalizzi A, Novelli A, Peng H, Rady Children's Institute for Genomic Medicine, Rodriguez D, Robbins SL, Rutledge SL, Scalise R, Schließke S, Shashi V, Srivastava S, Thiffault I, Topol S, Undiagnosed Disease Network, Qebibo L, Wieczorek D, Cravatt B, Haricharan S, Torkamani A, Friedman J
Brain 2022 Oct 21 ;145(10):3383-3390
The DNA damage repair landscape in Black women with breast cancer.
Mazumder A, Jimenez A, Ellsworth RE, Freedland SJ, George S, Bainbridge MN, Haricharan S
Ther Adv Med Oncol 2022 ;14:17588359221075458
